← Eichor
Study identifier: NCT07256704 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Hypnosis and Attention in Patients With a Neurological Disease (Stroke, Traumatic Brain Injury and Multiple Sclerosis)

Condition: Stroke · Traumatic Brain Injury · Multiple Sclerosis  ·  Sponsor: Luzerner Kantonsspital

PhaseNA
Planned participants48
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This feasibility study investigates the potential of hypnosis as a complementary therapy to improve attentional deficits and fatigue in patients with neurological diseases such as stroke, traumatic brain injury (TBI), and multiple sclerosis (MS). These patients often experience reduced spontaneous visual exploration and impaired functional independence despite current rehabilitation methods. By integrating hypnosis with standard care, and using EEG to monitor brain activity during hypnosis and sham-hypnosis sessions, this trial aims to evaluate the practicality, acceptability, and preliminary efficacy of hypnosis in enhancing attention and reducing fatigue.

This description comes directly from the study's public registry record.

Talk to the study team

Thomas Nyffeler, Prof. Dr. med.  ·  +41412055686  ·  thomas.nyffeler@luks.ch

Always discuss trial participation with your own doctor first.

Locations (1)

Luzerner KantonsspitalLucerne, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07256704